YOLFTbeta
Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc

CDIO · NASDAQ · Healthcare / Biotechnology

1.89USD+0.02 (+1.07%)

Price History

Full chart

Market Stats

Previous Close1.87
Open1.93
Day Range1.89 – 2.09
52-Week Range0.97 – 7.91
Volume38.85K
Market Cap5.77M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.90
Dividend Yield0.00%
Beta2.23
50-Day Avg1.85
200-Day Avg2.22

About

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Meeshanthini V. Dogan Ph.D.
  • Employees15
  • Headquarters311 West Superior Street, Chicago, IL, United States, 60654, USA
  • Websitehttps://cdio.ai

Leadership

  • Dr. Meeshanthini V. Dogan Ph.D.Co-Founder, CEO & Director · b. 1989
  • Ms. Elisa Michael Luqman Esq., J.D., M.B.A.CFO & Principal Accounting Officer · b. 1964
  • Mr. Timur Dogan Ph.D.Chief Technology Officer · b. 1989
  • Dr. Robert A. Philibert M.D., Ph.D.Co-Founder, Chief Medical Officer & Director · b. 1962

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue090195017.07K34.89K14.82K
Growth (%)--+5.44%+1696.32%+104.45%-57.51%
Cost of Revenue--16.00K111.62K276.35K398.13K
Gross Profit-90195017.07K34.89K14.82K
Gross Margin-100.00%100.00%100.00%100.00%100.00%
Operating Expense-621.35K4.55M7.26M8.40M6.50M
Operating Income-609.16K-620.45K-4.55M-7.24M-8.37M-6.48M
Operating Margin--68862.15%-478784.32%-42440.43%-23977.86%-43737.46%
EBITDA-598.50K-604.45K-4.64M-1.53M-8.09M-6.09M
EBITDA Margin--67086.35%-488945.79%-8966.90%-23182.77%-41047.14%
Net Income-605.16K-620.45K-4.66M-8.38M-8.38M-6.50M
Net Income Margin--68862.15%-490630.00%-49087.81%-24028.24%-43832.49%
R&D1.50K31.47K40.45K145.18K227.97K641.21K
R&D as % of Total Revenue-3492.56%4257.68%850.76%653.38%4325.21%
Interest Expense--06.74M18.64K14.80K
Interest Expense % of Total Revenue--0.00%39466.74%53.43%99.84%

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets446.38K1.10M6.25M4.46M10.62M7.77M
Total Liabilities386.01K33.88K1.95M1.50M1.06M793.06K
Total Equity60.37K1.07M4.30M2.96M9.56M6.97M
Cash237.09K512.77K4.12M1.28M7.83M5.11M
Total Debt--849.03K1.26M969.86K695.62K
Net Debt-237.09K-512.77K-3.27M-22.50K-6.86M-4.42M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow25.86K-585.29K-5.09M-5.67M-4.99M-5.73M
Investing Cash Flow-29.91K-364.03K-368.00K-794.29K-404.19K-419.31K
Financing Cash Flow240.00K1.23M9.06M3.63M11.94M3.43M
Capital Expenditure29.91K114.03K76.15K794.29K404.19K187.32K
Free Cash Flow-4.05K-699.32K-5.17M-6.47M-5.40M-5.91M
FCF to OCF-15.67%119.48%101.50%114.00%108.09%103.27%

Earnings

Report DateOct 19, 2021Mar 31, 2022May 12, 2022Aug 10, 2022Nov 7, 2022Mar 31, 2023May 15, 2023Aug 14, 2023Nov 13, 2023Feb 28, 2024May 15, 2024Aug 12, 2024Nov 13, 2024Mar 20, 2025May 15, 2025Aug 14, 2025Nov 12, 2025Feb 25, 2026Jun 3, 2026Aug 7, 2026Nov 11, 2026
EPS Estimate0.00----19.80-0.09-5.40-4.80-4.80-0.14-2.40-2.70-1.50-0.18-0.21-0.22-0.22----
EPS Actual0.00-0.02-0.03-0.530.60-0.3014.63-10.72-5.08-1.06-6.00-1.80-1.80-0.04-0.97-0.97-0.98-0.80-0.63-0.51-
Surprise----103.03%-233.33%370.93%-123.33%-5.83%-687.33%-150.00%33.33%-20.00%77.78%-361.90%-340.91%-345.45%----
Timing-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hours------

Key Statistics & Ratios

Market Cap5.77M
Enterprise Value465.18K
Trailing P/E0.00
Forward P/E0.00
Price / Sales399.37
Price / Book0.77
EPS-2.90
Book Value2.51
Revenue (TTM)14.45K
Gross Profit (TTM)14.45K
EBITDA-6.08M
Profit Margin0.00%
Operating Margin-27950.50%
Return on Equity-75.44%
Return on Assets-44.06%
Shares Outstanding2.96M
Shares Float2.84M
Beta2.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 60.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
6.52%
Insiders
8.31%
Retail / Other
85.17%

Top Institutional Holders

  • Jane Street Group LLC
    81.28K2.75%
  • HRT FINANCIAL LLC
    62.48K2.11%
  • BlackRock Inc
    34.71K1.17%
  • Geode Capital Management, LLC
    32.18K1.09%
  • Vanguard Capital Management, LLC
    20.16K0.68%
  • Citadel Advisors Llc
    19.07K0.64%
  • Renaissance Technologies Corp
    15.35K0.52%
  • Scientech Research LLC
    13.88K0.47%
  • UBS Group AG
    9.92K0.34%
  • Vanguard Fiduciary Trust Co
    3.97K0.13%
  • Tower Research Capital LLC
    2.19K0.07%
  • Wolverine Asset Management LLC
    1040.00%
  • Morgan Stanley - Brokerage Accounts
    1000.00%
  • SHP Wealth Management
    160.00%
  • Advisor Group Holdings, Inc.
    160.00%
  • SBI Securities Co Ltd
    100.00%
  • Citigroup Inc
    10.00%

Top Fund Holders

  • Fidelity Extended Market Index
    15.74K0.53%
  • Fidelity Series Total Market Index
    2.83K0.10%
  • Fidelity Total Market Index
    2.25K0.08%

Stock Splits

  • May 13, 20251:30